Grifols invests more than €200 million in fighting Alzheimer's

Barcelona, September 19, 2025. Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a global healthcare company and leader in plasma-derived medicines, has invested more than €200 million to-date in the fight against Alzheimer's disease. This investment, made over the last 20 years, is part of the company's efforts in innovation to develop potential new treatments for neurological diseases and other therapeutic areas.

Among its main investments in this field is the innovative AMBAR^® (Alzheimer's Management by Albumin Replacement) clinical program, based on the periodic removal of plasma and its replacement with a solution of albumin, a plasma protein. This Grifols clinical program has been shown to slow cognitive and functional decline in patients with mild to moderate Alzheimer's disease. Specifically, the primary efficacy variables evaluated [the ADAS-Cog (Alzheimer's Disease Assessment Scale - Cognitive) and ADCS-ADL (Alzheimer's Disease Cooperative Study - Activities of Daily Living) scales] showed a 61% reduction in disease progression for both measures in the cohort of patients with mild and moderate Alzheimer's disease.

The treatment is based on the hypothesis that much of the beta-amyloid, one of the proteins that accumulates in the brains of people with Alzheimer's, circulates in the plasma, bound to albumin. By removing this plasma, the displacement of beta-amyloid from the brain would be promoted, which would help limit the impact of the disease on the patient's cognitive functions. In addition, patients can also benefit from the antioxidant and anti-inflammatory properties of albumin.

This program, included in the medical guidelines of the renowned ASFA (American Society for Apheresis), has been in place since 2021 at the first AMBAR^® center, which the company opened in Barcelona in collaboration with the ACE Foundation. Due to its success, Grifols is currently in advanced talks with leading Spanish hospital groups to open new AMBAR centers in Spain and is also considering opening new facilities in Germany and the United Kingdom.

The project, the result of collaboration between Grifols, the ACE Foundation in Barcelona, and the Alzheimer's Disease Research Center at the University of Pittsburgh, is part of the company's comprehensive Alzheimer's research strategy, which began in 2004 after multiple preclinical trials, pilot studies and a phase II trial. The results have been published in the journal Alzheimer's & Dementia: The Journal of the Alzheimer's Association and presented at leading international conferences such as CTAD, AD/PD, and AAIC.